Challenges and opportunities for patients with advanced NSCLC
Eagerly anticipated results of the FLAURA trial
Promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma
What is durvalumab’s future as a treatment option in lung cancer?
LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC